Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brimonidine for Ocular Graft-vs-Host Disease
NCT02975557Phase 2Terminated
- Sponsor
- Akums Drugs
- Start
- May 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of brimonidine tartrate + sodium hyaluronate in ocular graft-versus-host disease (oGVHD) (3 arms), sponsored by Akums Drugs. Primary endpoint: Test Substance Tolerance at 12 weeks. Started May 2016; status: terminated.
02
Drugs
brimonidine tartrate + sodium hyaluronate
03
Conditions
ocular graft-versus-host disease (oGVHD)
Beyond the preview
Go deeper on NCT02975557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02975557.